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Maintenance of normal endothelial function is critical
to various aspects of blood vessel function, but its
regulation is poorly understood. In this study, we
show that disruption of baseline fibroblast growth
factor (FGF) signaling to the endothelium leads to
a dramatic reduction in let-7 miRNA levels that, in
turn, increases expression of transforming growth
factor (TGF)-b ligands and receptors and activation
of TGF-b signaling, leading to endothelial-to-mesen-
chymal transition (Endo-MT). We also find that Endo-
MT is an important driver of neointima formation in a
murine transplant arteriopathymodel and in rejection
of human transplant lesions. The decline in endothe-
lial FGF signaling input is due to the appearance of an
FGF resistance state that is characterized by inflam-
mation-dependent reduction in expression and
activation of key components of the FGF signaling
cascade. These results establish FGF signaling as
a critical factor in maintenance of endothelial homeo-
stasis and point to an unexpected role of Endo-MT in
vascular pathology.
INTRODUCTION
Maintenance of the normal vasculature is an active process.
Fibroblast growth factors (FGFs) have recently emerged as key
regulators of the normal vascular state (Hatanaka et al., 2011;
Murakami et al., 2008). Circulating and tissue-resident FGF1684 Cell Reports 2, 1684–1696, December 27, 2012 ª2012 The Autsignal via cognate tyrosine kinase receptors that require the
intracellular adaptor FRS2 for the initiation of mitogen-activated
protein kinase (MAPK) signaling (Eswarakumar et al., 2005).
Experimental evidence using various in vitro models points to
FGF’s role in inhibition of TGF-b signaling. Thus, FGF2 downre-
gulates TGF-bR1 expression, attenuates endothelial cell (EC)
responses to TGF-b (Fafeur et al., 1990), and antagonizes
TGF-b1-mediated smooth muscle a-actin (aSMA) expression
(Papetti et al., 2003). In addition, FGF can revert TGF-b1-induced
epithelial-to-mesenchymal transition (EMT) in epithelial cells via
the MAPK pathway (Ramos et al., 2010). These observations
suggest that loss of endothelial FGF signaling may lead to upre-
gulation of the TGF-b pathway and promotion of adverse
changes in the vasculature. However, the molecular mecha-
nisms linking FGF and TGF-b signaling cascades and the biolog-
ical role of FGF-dependent regulation of TGF-b signaling have
not been identified.
One likely consequence of dysregulated TGF-b signaling in
the vasculature is the development of neointima. Neointima
formation underlies a number of common diseases including
transplant vasculopathy, postangioplasty, and vascular graft
restenosis, hypertension, and atherosclerosis among others.
Despite decades of investigations, the origins of neointimal cells
still remains controversial with studies variously pointing to the
role of medial smooth muscle cell (SMC) proliferation (Costa
and Simon, 2005), vessel wall inflammation (Ohtani et al.,
2004), and adventitial angiogenesis (Khurana et al., 2004).
One potential contributor to neointima formation is the
process of endothelial-to-mesenchymal transition (Endo-MT).
Somewhat similar to EMT, Endo-MT is thought to result in endo-
thelial cells trans-differentiating into mesenchymal cell types,
including SMC-like and fibroblast-like cells. While Endo-MThors
has been implicated in several pathological processes including
cardiac fibrosis (Zeisberg et al., 2007b) and pulmonary hyperten-
sion (Kitao et al., 2009), its very existence is still controversial.
Similarly to EMT, Endo-MT is thought to be driven by TGF-b in
a SMAD-dependent and independent manner (Kitao et al.,
2009; Medici et al., 2011). However, factors leading to Endo-
MT under pathologic conditions or suppressing its occurrence
in the normal vasculature have not been identified.
In this study, we observed that a shutdown of endothelial FGF
signaling in normal ECs results in increased expression of TGF-
b ligands and receptors and activation of TGF-b signaling. In vitro
this resulted in a change in EC morphology and expression of
SMC markers. In vivo, using fate-mapped mice, we observed
neointima formation and extensive perivascular fibrosis. The
process was driven by a decline in endothelial expression of
let-7 miRNAs that normally maintain low levels of TGF-bR1
expression. The effects of FGF signaling shutdown on Endo-
MT induction could be mimicked by inhibition of let-7b or
let-7c expression in vitro and in vivo. Endo-MT was a critical
driver of neointima formation in a transplant arteriopathy model
in mice, was present in rejecting human transplants, and could
be reversed by treatment with let-7b mimics. These results
demonstrate that basal FGF signaling is required to maintain
high let-7 expression in the endothelium that in turn prevents
activation of TGF-b signaling and suppresses Endo-MT.
RESULTS
Basal FGF Signaling Suppresses TGF-b-Mediated
Endo-MT
To test the role of FGF signaling in ECs, we used RNA interfer-
ence in human umbilical artery endothelial cells (HUAECs) to
inhibit expression of FRS2, the key adaptor molecule involved
in FGF receptors signaling. Immunofluorescence staining
showed that while control HUAECs display a typical rounded/
cobblestonemorphology, FRS2 knockdown resulted in a distinct
change in cell shape accompanied by expression of smooth
muscle calponin (SM-calponin), a protein not normally ex-
pressed in the endothelium (Figure 1A). Western blotting
confirmed the appearance of this and other SMC markers in
FRS2 knockdown cells (Figure 1B). Fluorescence-activated cell
sorting analysis showed that both control and FRS2 knockdown
ECs expressed CD31 and were able to take up Di-acLDL, ruling
out SMC contamination (Figure 1C).
These findings suggest that following FRS2 knockdown ECs
are undergoing Endo-MT as defined by an acquisition of mesen-
chymal markers. Since TGF-b signaling has been implicated in
this process, we next examined TGF-b-related gene expression.
Quantitative real-time PCR analysis demonstrated a marked
increase in TGF-b1 and TGF-b2, all three TGF-b receptors, as
well as several collagen isoforms and other matrix proteins that
are stimulated by TGF-b signaling (Figures 1D and 1E). Western
blotting confirmed increased TGF-bR1 expression and activa-
tion of TGF-b signaling (Figure 1F). To verify that disruption of
FGF signaling induces TGF-b signaling and Endo-MT, HUAECs
were transduced with mutant forms of FRS2 that inhibit FGF
signaling or with a dominant negative FGFR1 (FGFR1-DN) (Fig-
ure S1A). A complete suppression of FGF signaling achievedCell Rewith expression of FGFR1-DN or Frs2a-6F constructs resulted
in increased TGF-b signaling (Figure S1B) and an increase in
smooth muscle and other mesenchymal marker expression
(Figure S1C).
To demonstrate that activation of TGF-b signaling following
FRS2 knockdown is indeed necessary and sufficient for Endo-
MT, several different experimental approaches were used.
Treatment of FRS2 knockdown ECs with the TGF-bR1 inhibitor
SB431542 significantly decreased SM-calponin, fibronectin,
and vimentin expression (Figure 1G). Similar results were seen
after transduction of a dominant negative TGF-bR1 construct
(TGF-bR1 K230R) (Figure 1H), while silencing SMAD2 expres-
sion with a specific small hairpin RNA resulted in a significant
decrease in SM-calponin, but not in fibronectin and vimentin
expression (Figure 1I). Finally, activation of TGF-b signaling in
the absence of FGF signaling suppression was achieved by
introduction of the wild-type TGF-bR1 together with TGF-b or
by expression of a constitutively active TGF-bR1 (TGF-bR1-
T202D) into HUAECs with a kinase dead mutant TGF-bR1-
K230R used as a control (Figures S2A and S2B). Thus achieved,
activation of TGF-b signaling resulted in increased expression of
smooth muscle (Figure S2C) and other mesenchymal markers
(Figure S2D).
FGF Controls TGF-bR1 Signaling via Regulation of let-7
miRNA Expression
We next examined the mechanism responsible for increased
expression of TGF-bR1 following FGF signaling shutdown. Anal-
yses of mRNA half-life showed a marked increase following
a knockdown of FRS2 expression (Figure 2A). This suggests
the presence of miRNA regulating TGFbR1 message stability.
In silico analysis identified binding sites for the let-7 family of
miRNAs with an exact match to the seed sequence of let-7 in
TGFbR1 30 UTR 75–82 and 3889–3895 (Figure 2B). At the same
time, miRNA array analysis demonstrated a >20-fold reduction
in expression of all let-7 family members (with let-7b and 7c
reduced 108- and 120-fold, respectively) following FRS2 knock-
down in ECs (Figure 2C).
To demonstrate that increased TGF-b signaling following FGF
suppression is directly due to changes in let-7 levels, we inhibited
let-7 expression using two alternative approaches. Transduction
of human umbilical vein endothelial cells (HUVECs) with LIN28,
a known regulator of let-7 biogenesis during embryonic develop-
ment (Viswanathan and Daley, 2010), resulted in increased
expression of genes in the TGFb pathway and smooth muscle
andmesenchymal markers (Figures 2D, left panel, and S3). Simi-
larly, HUVEC transduction with a let-7 ‘‘microsponge’’ construct
that effectively suppresses expression of all let-7 miRNAs also
led to a marked increase in TGFbR1, SM-calponin, and
HMGA2 (a known let-7 target) expression (Figure 2D, right panel).
We then examined if restoration of let-7 expression in ECswith
suppressed FGF signaling would, in turn, inhibit activation of
TGF-b signaling and Endo-MT induction. To this end, HUAECs
were transduced with let-7b or let-7c pre-miRs. Increased
TGF-bR1 expression and SMAD2 phosphorylation induced by
FRS2 knockdown were completely reversed by transduction
with either let-7b or let-7c as was the expression of all Endo-
MT markers (Figures 2E and 2F).ports 2, 1684–1696, December 27, 2012 ª2012 The Authors 1685
Figure 1. FRS2 Regulates Mesenchymal Marker Gene Expression via the TGF-bR1 Pathway
(A) Immunofluorescence staining of VE-cadherin (red) and SM-calponin (green) in control and FRS2 knockdown HUAECs. Nuclei were counterstained with TO-
PRO-3 (blue). Scale bar: 50 mm.
(B) Immunoblots of SMC markers in control and FRS2 knockdown HUAECs.
(C) Control or FRS2 knockdown HUAECs were analyzed by flow cytometry for CD31 and Dil-acLDL.
(D) Quantitative real-time PCR array mRNA expression profile of TGF-b family genes from control or FRS2 knockdown cells.
(E) Quantitative real-time PCR analysis of TGF-bRs and downstream target gene expression in control and FRS2 knockdown HUAECs. Data are presented as
mean ± SD, and two group comparisons were done with a two-tailed Student’s t test (*p < 0.05; ***p < 0.001 compared to control). b-actin was used to normalize
the variability in template loading.
(F) Immunoblots of TGF-bR1, Smad2, mesenchymal, and endothelial cell markers in control and FRS2 knockdown HUAECs.
(G–I) Quantitative real-time PCR analysis of SM-calponin and mesenchymal markers fibronectin and vimentin expression. Data are presented asmean ± SD, and
two group comparisons were done with a two-tailed Student’s t test (**p < 0.01; ***p < 0.001). b-actin was used to normalize the variability in template loading.
Data shown are representative of four independent experiments (except D). NS, not significant compared to control. See also Figures S1 and S2.The link between FGF signaling and let-7 expression was
then studied in vivo. Replacement of specific tyrosines in
FRS2 (FRS2a-2F) (Figure S1A) that are phosphorylated by FGF
biding to FGFR1 and activate ERK signaling results in a marked1686 Cell Reports 2, 1684–1696, December 27, 2012 ª2012 The Autreduction in FGF signaling and embryonic lethality (Gotoh
et al., 2004). Examination of Frs2a-2F embryos at E10.5 demon-
strated a gene dose-dependent reduction in let-7 levels
(Figure S4A).hors
Figure 2. FRS2 Knockdown Downregulates let-7 Family
(A) Control or FRS2 knockdown HUAECs were treated with DMSO or 10 mg/ml actinomycin D (ActD) for the indicated times. Quantitative real-time PCR was then
used to determine TGF-bR1 expression. 18S rRNA was used to normalize the variability in template loading.
(B) Alignment of let-7 sequences with the 30 UTRs of the human TGF-bR1.
(C) miRNA expression profiles assessed using quantitative real-time PCR miRNA arrays with cDNA from control or FRS2 knockdown cells.
(D) Quantitative real-time PCR of TGF-bR1 and SM-calponin in HUVECs transduced with Lin28, let-7 sponge expressing or empty vector. b-actin was used to
normalize the variability in template loading.
(E) Immunoblots of TGF-bR1, p-Smad2, Smad2, and FRS2 in control and FRS2 knockdown HUAECs transduced with let-7 lentiviruses.
(F) Quantitative real-time PCR analysis of TGF-bR1, TGF-b downstream target molecules, smooth muscle marker and mesenchymal marker gene expression in
control and FRS2 knockdown HUAECs transduced with let-7 lentiviruses (*p < 0.05; **p < 0.01; ***p < 0.001 compared to control). b-actin was used to normalize
the variability in template loading. Data shown (A and D-F) are representative of three independent experiments.
(G) Mice were injected intravenously with control or cholesterol formulated antagomir-let-7b/c (single injection of 2 mg/kg) and the liver endothelial cells were
isolated at 6 days. Expression of let-7miRNAs were analyzed by quantitative real-time PCR. SNORD66 was used to normalize the variability in template loading
(***p < 0.001; NS: not significant compared to control).
(H) Gene expression levels of K-ras, N-ras, HMGA2, CDK6, CDC25A, TGF-bR1, and vimentin in liver endothelial cells of mice treated with control or formulated
antagomir-let-7 at 6 days. b-actin was used to normalize the variability in template loading (*p < 0.05; ***p < 0.001 compared to control).
(I) Immunofluorescence staining of CD31/vimentin (Nuclei were counterstained with DAPI (blue, scale bar: 7 mm.) in liver sections of mice treated with control or
formulated antagomir-let-7 at 6 days.
(J) Quantification of liver ECs expresses vimentin in mice injected with control or formulated antagomir-let-7 (***p < 0.001 compared to control).
See also Figures S3 and S4.FGF signaling in adult mice can be inhibited by administration
of an FGF trap construct (sFGFR1-IIIC) (Murakami et al., 2008).
To demonstrate construct effectiveness, exposure of culturedCell ReHUVECs to Ad-sFGFR1-IIIc resulted in a distinct morphological
change (Figure S4B), suppression of let-7 expression (Fig-
ure S4C), and induction of Endo-MT markers including SM22a,ports 2, 1684–1696, December 27, 2012 ª2012 The Authors 1687
Figure 3. Inflammatory Cytokines (IFN-g, TNF-a, and IL-1b) Downregulate FGF Receptors, thereby Rendering ECs Less Responsive to FGF
In Vitro and In Vivo
(A) Quantitative real-time PCR analysis of smooth muscle and mesenchymal marker gene expression in control and human IFN-g treated HUVECs (*p < 0.05;
**p < 0.01; ***p < 0.001 compared to control). b-actin was used to normalize the variability in template loading.
(B) Immunoblots of smooth muscle and mesenchymal markers in control and human IFN-g treated HUVECs.
(C) HUVECs were treated with human IFN-g (10 ng/ml), human TNF-a (10 ng/ml), or human IL-1b (10 ng/ml) in complete growth medium for 6 days followed by
incubation in0.5%FBSstarvationmedium for 18hr.Cellswere treatedwith FGF2 (50ng/ml) for indicated times. Immunoblotsof FGFsignalingdownstream targets.
(D) Quantitative real-time PCR analysis of mature let-7 expression in control and human IFN-g treated HUVECs. SNORD47was used to normalize the variability in
template loading. Data shown (A–D) are representative of four independent experiments.
(E) Left: Immunofluorescence staining of p-ERK in adjacent aorta and graft sections in Cdh5-CreERT2;mT/mG mice. Scale bar: 10 mm. Right: Quantification of
endothelial cell express p-ERK in mice injected with FGF2 (***p < 0.001 compared to adjacent aorta).
See also Figures S5 and S6.SM-calponin, and fibronectin (Figures S4D and S4E). In agree-
ment with these in vitro data, Ad-sFGFR1-IIIc injection into
mice led to their detection in the host circulation and a significant
reduction in let-7 miRs expression in primary ECs isolated from
hearts and livers of these animals (Figures S4F and S4G).
To determine if reduction in let-7 expression would have the
same effects in vivo as suppression of FGF signaling, we directly
targeted let-7b and let-7c miRNAs in mice using cholesterol
formulated antagomirs for improved stability and delivery effi-
ciency (Love et al., 2010). Analysis of let-7 miRNAs expression
6 days after a single tail vein injection of 2 mg/kg of let-7b/c an-
tagomirs in primary liver ECs demonstrated a significant reduc-
tion in expression of let-7b and let-7c miRNA in antagomir-
treated compared to control mice while other family members
were not affected (Figure 2G). This reduction in let-7b/c levels
was further confirmed by increased expression of several known
let-7 targets including K-RAS, N-RAS, HMGA2, CDK6, and
CDK25A (Figure 2H). In agreement with the in vitro data, reduc-
tion in let-7b/c expression led to an increase in TGF-bR1 and
vimentin expression (Figure 2H). Finally, immunocytochemical
examination of blood vessels in the liver of let-7 antagomir-
treated mice demonstrated increased expression of vimentin in
luminal ECs, consistent with Endo-MT (Figures 2I and 2J).1688 Cell Reports 2, 1684–1696, December 27, 2012 ª2012 The AutInflammation-Dependent Suppression of FGF Signaling
The results of the in vitro and in vivo studies presented above
demonstrate that decreased FGF signaling leads to reduction
in let-7 expression and initiation of TGF-b-dependent Endo-
MT. To demonstrate the relevance of this biology to disease
settings, we next examined if Endo-MT occurs in transplant
rejection, a process associated with high local interferon-g
(IFN-g) production that has been reported to suppress FGF
signaling (Friesel et al., 1987).
Treatment of HUVECs in culture with IFN-g led to increased
expression of a let-7-dependent gene HMGA2, an increase in
TGFbR1 and SMAD2 levels and a large increase in the expres-
sion of SMC and other mesenchymal marker expression,
including Notch3, SM22a, fibronectin, and vimentin (Figures 3A
and 3B). Of note, there was a profound reduction in FGFR1
expression and almost full suppression of FGF signaling
(Figure 3C). Treatment of ECs with tumor necrosis factor
(TNF)-a and interleukin (IL)-1b led to a similar reduction in FGF
signaling (Figure 3C), while other inflammatory cytokines such
as IL-6, MCP-1, and VEGF had no such effect (Figures S5A–
S5C). In agreement with the observed reduction of FGF
signaling, exposure of HUVECs to IFN-g led to a profound
decrease in let-7 miRs expression (Figure 3D).hors
We next employed a mouse transplant rejection model
characterized by intense local inflammatory responses around
the rejecting graft and endothelial fate mapped mice that were
generated by crossing Cdh5-CreER2 and mT/mG (‘‘tomato’’)
mouse lines (both on a C57BL/6 background) followed by activa-
tion of the Cre gene by tamoxifen administration from P2 to P20
(Figure S6A). This results in permanent marking of all EC and EC-
derived cells with green fluorescent protein (GFP). Analysis of
arteries from these mice demonstrated uniform GFP expression
in the luminal ECs with a total absence of all SMC (Notch3,
aSMA, SM22a) or mesenchymal (vimentin, collagen) markers
(Figure S6B).
Engraftment of an aortic segment from BALB/c mice into
Cdh5-CreERT2-mT/mG (C57BL/6 background) mouse aorta
leads to intense graft inflammation and rejection over the next
2–3 weeks. To test the effect of this inflammatory response on
endothelial FGF signaling, the mouse hosts of allogeneic artery
grafts were intravenously injected with FGF2 at 2 weeks postop-
eratively and sacrificed 15 min later. Immunocytochemical anal-
ysis for FGF signaling demonstrated virtually no p-ERK signal in
graft luminal ECs, while luminal ECs from the adjacent normal
arterial segment revealed intense p-ERK signal (Figure 3E).
Examination of the graft 2 weeks after transplantation showed
that 10.1% of neointimal SMC (defined by expression of either
Notch3 or aSMA) expressedGFP, which indicated an endothelial
origin (Figures 4A and 4B). Furthermore, a very high proportion of
ECs in the neointima (79%) expressed Notch3 and aSMA
(Figures 4A and 4C), demonstrating very extensive Endo-MT.
To examine the effect of FRS2a expression disruption on this
process, we crossed Frs2afl/fl mice onto mT/mG background.
FRS2a expression was then inactivated by crossing these
mice with Cdh5-CreERT2 driver line (Cdh5-CreERT2; FRS2iDEC)
and then activating Cre expression on postnatal day 5 (P5).
Inhibition of FGF signaling by endothelial-specific Frs2a
deletion or suppression of let-7 expression with antagomirs re-
sulted in a further statistically significant (p < 0.05) increase in
the number of GFP+ SMC (Figures 4A and 4B), while the propor-
tion of neointimal ECs with SMC markers increased to nearly
100% (Figure 4C).
Luminal ECs revealed even more extensive changes: 61%
of graft lumen ECs expressed Notch3 and aSMA with the
extent of Endo-MT increasing to 80%–90% in Cdh5-CreERT2;
FRS2iDEC mice or following let-7 anti-miR administration (Fig-
ure 4D). Collagen deposition, another feature of Endo-MT, and
neointima thickness of transplanted arteries were significantly
increased by both endothelial cell Frs2a deletion and let-7 anta-
gomir treatment (Figures 4E and 4F).
To test the ability of let-7 miR to rescue this phenotype we
used chemically synthesized double stranded let-7bmiRmimics
packaged in liposomal-formulated lipid nanoparticles (LNPs)
(Love et al., 2010). The effectiveness of delivery against endothe-
lial targets was assessed by first determining the dose response
for inhibition of target gene expression. A single intravenous
injection of LNPs carrying from 0.03 to 2.2 mg/kg of anti-Tie2
siRNA demonstrated 70% inhibition of Tie2 expression in liver
and heart ECs after 72 hr (Figures S7A and S7B) persisting
with 30 day half-life in both organs (Figures S7C and S7D).
Similar results were seen with siRNA formulations targetingCell ReIcam2 (Figures S7E and S7F), Vegfr2 (Figures S7G and S7H),
and Cdh5 (Figures S7I and S7J). In contrast, no detectable
reduction of any tested gene was observed with a LNP-
formulated luciferase siRNA (LUC) or saline (Figures S7A, S7B,
and S7E–S7J), indicating that silencing is specific to the siRNA
and is not caused by the liposomal carrier. To demonstrate the
physiological significance of this level of inhibition, we carried
out an Evans blue assay in mice treated with 0.7 mg/kg of
LNP Cdh5 siRNA. Following knockdown, there was a significant
increase in ECs permeability compared to control mice
(Figure S7K).
Using the LNP preparation described above, let-7 mimics
(0.5 mg/kg) were injected every other day starting at postopera-
tive day 7 (for a total of four injections) and the grafts were
harvested on day 14. Administration of these mimics to grafted
mice led to a significant reduction in the number of neointimal
SMC of endothelial origin (GFP+/Notch3+ or aSMA+ cells: from
10.1% in the absence of treatment to 3% in mimic-treated
mice, p < 0.05) (Figures 4A and 4B) as well as in the proportion
of neointimal ECs undergoing Endo-MT (from 79% to 20.3%,
p < 0.01; Figures 4A and 4C). Equally significantly, there was
a dramatic decrease in the proportion of luminal ECs undergoing
Endo-MT (from 61% to 33.7%, p < 0.01; Figures 4A and 4D)
and a dramatic reduction in collagen deposition and neointima
thickness (Figures 4A, 4E, and 4F).
To determine if a similar phenomenon occurs in human
disease, we examined coronary arteries (n = 8) from explanted
chronically rejecting hearts. Compared to normal human coro-
nary arteries (Figure 5A), the majority (79.8%) of luminal ECs in
arteries procured from patients with chronic cardiac graft rejec-
tion expressed the SMC marker, Notch 3 (Figures 5B, 5C, and
5E). Analysis of the neointima showed that similar to the mouse
transplant model, Endo-MT was extensive with 76% of neointi-
mal ECs expressing Notch3 (Figures 5D and 5F) and accounted
for a significant portion (9.6%) of neointimal SMC (Figure 5G).
Transplantation of a segment of human coronary artery into
immunodeficient mouse aorta reconstituted with allogeneic
human peripheral blood mononuclear cells (PBMCs) to induce
graft rejection (Rao et al., 2008) was then used to verify the
occurrence of Endo-MT in human endothelium. Three weeks
following PBMC injection, rejecting human arteries demon-
strated extensive neointima formation (compare Figure 5H to
5I) and widespread expression of Notch3 in luminal and neointi-
mal ECs (Figures 5J and 5K). Quantitative analysis demonstrated
that 84.7% of all luminal and 77% of neointimal ECs expressed
Notch3 (Figures 5L and 5M), while 10.4% of neointimal SMC ex-
pressed EC markers (Figure 5N).
Finally, to examine the frequency of this phenomenon in other
settings, we evaluated two other in vivo models characterized by
various extents of neointima formation and vascular inflamma-
tion- wire injury and vein-to-artery grafting. Wire injury to the
common femoral artery in Cdh5-CreERT2;mT/mGmice resulted
in neointima development with 5.2% of neointimal cells demon-
strating GFP expression (Figure 6A). Grafting mouse vena cava
into the aorta of syngeneic Cdh5-CreERT2;mT/mG mice was
also associated with evidence of Endo-MT in the neointima 3%
at 2 weeks and 6.7% at 4 weeks. Luminal ECs of the vein
graft also displayed extensive Endo-MT with 31% expressingports 2, 1684–1696, December 27, 2012 ª2012 The Authors 1689
Figure 4. Endo-MT Participates in Mouse Arteriosclerosis
(A) Histological analysis of artery grafts by immunostaining with anti-Notch3, anti-aSMA, and anticollagen 1. Cdh5-GFP+/Notch3+ (red) and Cdh5-GFP+/aSMA+
(red) colocalization indicates Endo-MT and appears yellow. Nuclei were counterstained with DAPI (blue). Scale bar: 10 mm for Notch3 and aSMA and 63 mm for
collagen 1. L, lumen; N, neointima; white triangle indicates endothelial cells; yellow triangle indicates IEL (internal elastic lamina); arrows indicate endothelial cells
express SMC markers.
(B) Percentage of Notch3+ (left) or aSMA+ (right) cells that were Cdh5-GFP+ in neointima (*p < 0.05; **p < 0.01 compared to control).
(C) Percentage of Cdh5-GFP+ cells that were Notch3+ (left) or aSMA+ (right) in neointima (**p < 0.01 compared to control).
(D) Percentage of Cdh5-GFP+ cells that were Notch3+ (left) or aSMA+ (right) in lumen (*p < 0.05; **p < 0.01; ***p < 0.001 compared to control).
(E and F) Morphometric assessment of collagen 1 area and artery graft neointima thickness was performed by computer-assisted microscopy (*p < 0.05; **p <
0.01 compared to control). PBS (n = 7 mice/group), Luc-control (n = 6 mice/group), Cdh5-CreERT2; Frs2iDEC (n = 4 mice/group), antagomir-let-7 (n = 9 mice/
group), and let-7b mimics (n = 6 mice/group).
See also Figure S7.mesenchymal markers 2 weeks after grafting and 45.6% after
4 weeks (Figure 6B).
DISCUSSION
The data in the present study indicate that basal FGF signaling
in ECs is required to maintain let-7 miRNA expression. High
let-7 levels, in turn, are required for suppression of TGF-b
signaling and inhibition of Endo-MT. Finally, Endo-MT itself is
an important contributor to the development of neointima in1690 Cell Reports 2, 1684–1696, December 27, 2012 ª2012 The Auta number of disease states characterized by FGF signaling
resistance. Thus, FGF control of let-7 expression directly regu-
lates TGF-b signaling, links these two critical growth factor
signaling pathways, andmaintains the normal state of the vascu-
lature (Figure 7).
FGFs exert a plethora of effects on a large number of cell types
(Eswarakumar et al., 2005). In the vascular system, FGF signaling
plays a protective role with ongoing FGF stimulation required for
the maintenance of vascular system integrity (Hatanaka et al.,
2011; Murakami et al., 2008) and VEGFR2 expression (Murakamihors
Figure 5. Endo-MT Participates in Human Graft Arteriosclerosis
(A and B) Representative images of human CD31 and Notch3 immunofluorescent staining of human normal and chronically rejecting human coronary arteries.
Scale bar: 62 mm. L indicates lumen; white triangle indicates IEL (internal elastic lamina).
(C and D) High-power images of human chronic rejection coronary artery lumen and neointima ECs colocalized with Notch3 staining. Scale bar, 16 mm. Arrows
indicate endothelial cells express SMC markers.
(E) Percentage of CD31+ cells that were Notch3+ in lumen (***p < 0.001 compared to normal artery).
(F) Percentage of CD31+ cells that were Notch3+ in neointima (Ø, not detected).
(G) Percentage of Notch3+ cells that were CD31+ in neointima (Ø, not detected).
(H and I) Representative images of human CD31 and Notch3 immunofluorescent staining of human coronary artery transplants in SCID/beige mice reconstituted
with or without human PBMCs. Scale bar: 62 mm. L indicates lumen; white triangle indicates IEL (internal elastic lamina).
(J and K) High-power images of artery graft treated with human PBMC lumen and neointima ECs colocalized with Notch3 staining. Scale bar: 16 mm. Arrows
indicate endothelial cells express SMC markers.
(L) Percentage of CD31+ cells that were Notch3+ in lumen (***p < 0.001 compared to no PBMC).
(M) Percentage of CD31+ cells that were Notch3+ in neointima (Ø, not detected).
(N) Percentage of Notch3+ cells that were CD31+ in neointima (Ø, not detected).et al., 2011). The current study expands this FGF function by
demonstrating the role of ongoing FGF signaling in prevention
of Endo-MT and implicates let-7 miRNA as the key player in
this process.
let-7 miRNA family was originally identified in Caenorhabditis
elegans as a regulator of developmental timing and cell prolifer-
ation (Reinhart et al., 2000). The family is highly conserved across
the entire phylogenetic tree and in mice and humans it consists
of 11 very closely related genes encoded on three different chro-
mosomes (Roush and Slack, 2008). To date, let-7 miRs have
been implicated in the control of numerous events duringCell Reembryogenesis including nervous system and liver development
(Maller Schulman et al., 2008), tumor suppression (Zhang et al.,
2007), and inhibition of cell proliferation (Johnson et al., 2007),
while recent studies have indicated their involvement in EMT
in tumors including a suggestion that an increase in let-7b
levels reverses this process (Li et al., 2009). let-7 miRNAs are
also highly expressed in ECs and are considered proangiogenic
(Urbich et al., 2008).
Despite these important biological roles, little is known about
the regulation of let-7 biogenesis. During embryonic develop-
ment, RNA binding proteins LIN28a/b selectively block itsports 2, 1684–1696, December 27, 2012 ª2012 The Authors 1691
Figure 6. Endo-MT in Femoral Artery Wire Injury and Vein Adaptation Models
(A) (a and b) Anatomy of the hindlimb vasculature. Blue lines indicate denuded endothelium layer. A, artery; V, vein; asterisks indicate wire inserted site. (c and d)
Representative images of cross sections of the uninjured (left) and injured (right) femoral arteries. (e and f) Immunofluorescence staining of aSMA (red) in injured
femoral artery sections 3 weeks after injury. L, lumen; N, neointima; M, media.
(B) (a) Schematic of vein to artery grafting. (b and c) Immunofluorescence staining of CD31 (red) and aSMA (red) in low power magnification of inferior vena cava
(IVC). (d) Immunofluorescence staining of aSMA (red) in high power magnification of IVC. (e and f) Immunofluorescence staining of CD31 (red) and aSMA (red) in
low power magnification of vein grafts. (g–i) Immunofluorescence staining of CD31 (red) in high power magnification of vein grafts 2 and 4 weeks after trans-
plantation. (h and j) Immunofluorescence staining of aSMA (red) in high-power magnification of vein grafts 2 or 4 weeks after transplantation.maturation (Hagan et al., 2009; Lehrbach et al., 2009),while a het-
eronuclear ribonucleoprotein A1 (hnRNPA1) inhibits its process-
ing by DROSHA (Michlewski and Ca´ceres, 2010). LIN28 is not
expressed in the adult endothelium and we observed no
increase in hnRNPA1 expression after FGF blockade (data not
shown). Our data suggest that homeostatic FGF stimulation is
essential for continued let-7 expression but the mechanism of
this effect is uncertain. let-7 family, in turn, has been indirectly
linked to the regulation of several TGF-b family members
including TGF-bR1 (Tzur et al., 2009).
Our study provides strong evidence supporting the link
between FGF signaling, let-7 expression, and TGF-b. In cell
culture studies, suppression of FGF signaling using several
different approaches uniformly resulted in a marked (up to 120-
fold) decrease in let-7 expression. In vivo, let-7 levels were
dramatically decreased in embryos with reduced FGF signaling1692 Cell Reports 2, 1684–1696, December 27, 2012 ª2012 The Aut(Frs2a-2F mutants), while systemic administration of a pan-
FGF trap, sFGFR1-IIIc, reduced let-7 levels in endothelial cells
fromdifferent organs. In each case, loss of FGF signaling-depen-
dent let-7 expression was associated with increased TGF-
b family member expression, activation of TGF-b signaling and
the appearance of Endo-MT markers.
The fact that the change in let-7 levels itself and not some
other effect of blocking FGF signaling is responsible for the up-
regulation of TGF-b signaling and Endo-MT is supported by
a number of observations. In vitro studies show that reduction
in let-7 expression in ECs induced by antagomirs, a pan-let-7
sponge or expression of the let-7 suppressor LIN28A leads to
increased expression of TGF-b, TGF-bR1, and classic TGF
target genes such as collagen or vimentin. Furthermore, ECs
demonstrated a dramatic morphological change consistent
with Endo-MT and expression of a number of smooth musclehors
Figure 7. Schema of FGF-Dependent Regulation of TGF-b Signaling
and Endo-MTand other mesenchymal markers. Similarly, in vivo antagomir
suppression of let-7b/c expression also led to increased TGF-
bR1 expression and appearance of Endo-MT markers. Most
importantly, restoration of let-7b levels in the endothelium using
modified let-7b mimics and a delivery system designed to facil-
itate miRNA delivery to the endothelium, reversed the effect of
FGF blockade or let-7 antagomir treatment on expression of
Endo-MT markers and its functional consequences. While all
let-7 family members are expressed in ECs, we chose let-7b
because it demonstrates, along with let-7c, the most dramatic
reduction in expression upon FGF signaling withdrawal and
because of all let-7 let-7b has the best complementarity with
TGFbR1 (Tzur et al., 2009).
The existence of an Endo-MT phenomenon still remains
a matter of intense debate as are its contributions to human
pathology. In addition to TGF-b, two other signaling pathway,
Notch (Chang et al., 2011) and Tie-1 (Garcia et al., 2012), have
also been reported to induce it. The molecular details, however,
remain sparse. While there is a significant body of evidence
linking TGF-b signaling to EMT, its role in Endo-MT is much
less established. Several studies have reported that a prolonged
stimulation of ECs in vitro with TGF-b can induce Endo-MT (Zeis-
berg et al., 2007a) but there are no studies demonstrating
the ability of TGF-b to induce Endo-MT in vivo. TGF-b is thought
to induce Endo-MT via SMAD-dependent activation of SNAIL
(Kitao et al., 2009). Endo-MT has been reported to occur in the
setting of cardiac, renal, pulmonary, cancer and age-related
fibrosis (Ghosh et al., 2010; Zeisberg et al., 2007a, 2007b). TheCell Recurrent study strongly supports the reality of an Endo-MT
phenomenon and expands its biological role.
In particular, we have demonstrated that Endo-MT plays an
important role in neointima formation, a process underlying
a number of important cardiovascular disease states. In the
transplant model, Endo-MT accounted for 10% of SMC in
the neointima, while80%of luminal ECs demonstratedmesen-
chymal transition. This is highly significant as, so transformed,
these cells can be expected to secrete large amounts of collagen
and other ECM proteins thus contributing to vessel fibrosis.
Indeed, extensive fibrosis was evident in endothelial-specific
Frs2a deletion or let-7 antagomir administration. Furthermore,
the acquisition of a mesenchymal phenotype by luminal ECs is
likely to lead to endothelial dysfunction, such as an increase
vascular permeability or potentiate leukocyte transmigration
(Murakami et al., 2008).
The trigger for the occurrence of Endo-MT is the loss of FGF
signaling. While many factors can and do affect this process,
the occurrence of FGF resistance is clearly associated with
inflammation. We traced this link to the ability of key inflamma-
tory mediators, including IFN-g and TNF-a, to reduce FGFR1
expression and markedly decrease FGF-dependent ERK activa-
tion. Thus, conditions associated with intense vascular inflam-
mation such as allogeneic artery transplantation, induce an
extensive Endo-MT response. In other models of vascular injury
where the loss of FGF signaling is less profound, such as wire
artery injury or vein-to-artery grafting, Endo-MT still occurs but
to a more limited extent. Beyond vascular injury, Endo-MT has
been reported in a number of pathological settings including
acute myocardial infarctions (Zeisberg et al., 2007b) and acute
kidney injury (Basile et al., 2011) that are also characterized by
an intense inflammatory component.
Most importantly, Endo-MT clearly occurs in human disease.
Indeed, eight out of eight human arteries from chronically reject-
ing cardiac allografts demonstrated clear evidence of Endo-MT
and human arteries transplanted into immunodeficient mice re-
constituted with allogeneic human PBMC underwent Endo-MT
with the same frequency as allogeneic mouse artery grafts.
In summary, FGF regulates endothelial TGF-b signaling by
controlling TGF-b, TGF-bR1, and SMAD2 expression via control
of let-7 levels. The emergence of an FGF resistance state and
a reduction in FGF signaling input leads to a profound decrease
in let-7 levels and increased TGF-b signaling culminating in
Endo-MT that, in turn, leads to neointima formation and fibrosis.
EXPERIMENTAL PROCEDURES
Primary Mouse Endothelial Cell Isolation and Culture
Primary mouse endothelial cells were isolated from the heart and liver as
described (Murakami et al., 2011).
let-7 Family Microsponge Construction
A let-7 microsponge of 273 nt was constructed containing nine bulged
binding sites (one for each of the let-7 family members: let-7a, let-7b, let-7c,
let-7d, let-7e, let-7f, let-7g, let-7i, and mir-98). The let-7 family microsponge
was synthesized by the annealing and ligation of six single-strand chemically
synthesized DNA fragments. The bulged binding sites were designed using
the canonic rules for microRNA binding sites (Filipowicz et al., 2008). The
273 nt let-7 family microsponge was subcloned in tandem to multiply the
binding sites.ports 2, 1684–1696, December 27, 2012 ª2012 The Authors 1693
Western Blot Analysis
Cells were lysed with T-PER (Thermo Scientific) containing complete mini
protease inhibitors (Roche) and phosphatase inhibitors (Roche). Total protein
(20 mg) from each sample was resolved on a 4%–12% Bis-Tris Gel (Bio-Rad)
with MOPs Running Buffer (Bio-Rad), transferred to nitrocellulose membranes
(Bio-Rad) and probed with antibodies. Chemiluminescence measurements
were performed using SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific).
RNA Isolation, Quantitative Real-Time PCR, and Gene Expression
Profiling
RNA was isolated using RNeasy plus Mini Kit (QIAGEN) and converted to
cDNA using iScript cDNA synthesis kit (Bio-Rad). Quantitative real-time PCR
was performed using Bio-Rad CFX94 (Bio-Rad) by mixing equal amount of
cDNAs, iQ SYBR Green Supermix (Bio-Rad), and gene-specific primers. All
reactions were done in a 25 ml reaction volume in duplicate. Data were normal-
ized to endogenous b-actin. Primers are listed in Table S1. Quantitative real-
time PCR analysis of 84 TGF-b-related and EMT-related genes was performed
using Human TGF-b BMP signaling pathway (PAHS-035D, QIAGEN) RT2
Profiler PCR Arrays and run on a Bio-Rad CFX96 machine (Bio-Rad). Data
analysis was done using manufacturer’s integrated web-based software
package with cycle threshold (Ct)-based fold-change calculations.
MicroRNA Target Prediction
To identify potential miRNA binding sites within the 30UTR of TGFbR1, the
following bioinformatic databases were used: TargetScan (http://www.
targetscan.org), PitTar (http://pictar.mdc-berlin.de), and DIANA-microT v3.0
(http://diana.cslab.ece.ntua.gr/).
microRNA Real-Time PCR Analysis
Quantitative real-time PCR analysis of 88 miRNA was performed using Human
Cell Differentiation & Development RT2 Profiler PCR Arrays (MAH-103A,
QIAGEN). Validation of microRNA array data was performed with the RT2
miRNA qPCR Assays and RT-PCR Primer Sets (QIAGEN). Individual miRNA
expression was normalized in relation to expression of small nuclear
SNORD47 (for human) or Snord66 (for mouse). PCR amplification consisted
of 10 min of an initial denaturation step at 95C, followed by 45 cycles of
PCR at 95C for 30 s, 60C for 30 s.
Generation of Mice and Embryos
Frs2flox/flox (Lin et al., 2007) and Frs2a-2F (Gotoh et al., 2004) mice were previ-
ously described. Cdh5-CreERT2 (gift from R.H. Adams, Max Planck Institute,
Munster) transgenic mice were crossed with mT/mG [B6,129(Cg)-Gt(ROSA)
26Sortm4(ACTB-tdTomato,-EGFP)Luo/J] (JAX SN:007676) mice to generate EC-
specific reporter mice. For fate mapping of Cdh5-GFP expressing cells,
Cdh5CreERT2;mT/mG pups were pipette-fed with 0.05 mg/g tamoxifen solu-
tion (20 mg/ml stock solution in corn oil) every other day ten times.
let-7 miRNA Lipid Formulation
Synthesis of let-7b Antagomirs
Antagomirs to let-7b and let-7c were synthesized as described (Kru¨tzfeldt
et al., 2005): anti-let-7b, 50- asasccacacaaccuacuaccsuscsas-Chol-30; and
anti-let-7c, 50 asasccauacaaccuacuaccsuscsgs-Chol-30. The lowercase letters
represent 20-OMe-modified nucleotides; subscript ‘‘s’’ represents a phosphor-
othioate linkage; and ‘‘Chol’’ represents cholesterol linked through a hydroxy-
prolinol linkage. Anti-let-7b and anti-let-7c were encapsulated in LNPs using
the same method and composition as previously described for C12-200-
siRNA formulations (Love et al., 2010). Particle size was determined by
dynamic light scattering (Zetasizer Nano ZS; Malvern, UK). Themean diameter
for anti-let7b-LNP was 145 nm and for anti-let7c-LNP was 160 nm.
Synthesis of let-7b Mimics
Chemically modified miRNA mimics were synthesized at Alnylam Pharmaceu-
ticals (Cambridge, MA). The sequences for the mature strands of let-7b after
processing by DICER, mmu-let-7b-5p (mmu-let-7b, MIMAT0000522), and
mmu-let-7b-3p (mmus-let-7b*, MIMAT0004621), were obtained from the miR-
base (http://www.miRbase.org). 2-O-methyl-nucleotide modifications (indi-1694 Cell Reports 2, 1684–1696, December 27, 2012 ª2012 The Autcated in lowercase) were introduced to both strands to decrease the likelihood
of triggering an innate immune response. Double-stranded miRNA mimics
were obtained after annealing equimolar amounts of the chemically modified
5p and 3p strands: mi-let-7bL, for lightly modified (5p 5
0-UGAGGuAGuAG
GUUGUGUGGUU-30, 3p 50-CuAuAcAACCuACUGCCUUCCC-30); and mi-let-
7bH, for heavily modified, (5p 5
0-UGAGGuAGuAGGUUGUGUGGUU-30, 3p
50-cuAuAcAAccuAcuGccuuccc-30). LNPs formulated with siRNA targeting
luciferase, siLuc, were used as control.
miRNA Formulation in Lipid Nanoparticles
microRNA mimics and siLuc were encapsulated in LNPs formulated with the
lipid C12-200, using the same protocol and composition as previously
described. The mean diameter range for all LNPs was 54–59 nm.
In Vivo sFGFR1-IIIc Adenovirus Administration and let-7 Antagomir
Delivery
sFGFR1-IIIc adenovirus (Murakami et al., 2008) was administered at a dose of
5 3 1010 viral particles per mouse via lateral tail vein injection. Control mice
were given equivalent volumes of sterile PBS. Serum level of sFGFR1-IIIc
was measured by a Human IgG Subclass Profile kit (Invitrogen). For let-7
antagomir delivery, mice were administered with either 1:1 mixture of anti-
let7b-LNP and anti-let7c-LNP or PBS at 2 mg/kg body weight in 0.1 ml per
injection via lateral tail vein. Measurements of miRNA or mRNA levels in ECs
were performed 6 days after the injection.
In Vivo let-7 Antagomir and let-7 Mimics Delivery in Mouse Arterial
Transplant Model
For let-7 experiment, 7 days after arterial transplant, mice were injected with
four doses of let-7 antagomir (2 mg/kg), luciferase-control (0.5 mg/kg), and
let-7bmimics (0.5mg/kg) in 0.1ml per injection via jugular vein every other day.
Human Tissue
Deidentified human coronary arteries were obtained from organ donors with
normal cardiac function, from end-stage cardiomyopathy patients undergoing
heart transplantation, or from cardiac allograft recipients with chronic rejection
at autopsy or undergoing retransplantation. Tissue collection and analysis was
approved by the review boards of Yale University School of Medicine, the New
England Organ Bank, and the University of British Columbia.
Endo-MT Animal Models
All experiments were performed under protocols approved by Yale University
Institutional Animal Care and Use and Human Investigation Committees.
Arterial Transplant Models
For mouse to mouse major mismatch arterial transplant model, segments
of thoracic aorta from male, 4- to 5-week-old BALBc/J mice were
interposed into the infrarenal aortae of male recipient, 10- to 12-week-old
Cdh5CreERT2;mT/mG mice using an end-to-end microsurgical anastomotic
technique.
For human to mouse arterial transplant model, adjacent segments of human
coronary artery from surgical specimens or cadaveric organ donors were
implanted into the infrarenal aortae of 8- to 12-week-old CB.17 severe
combined immunodeficient (SCID)/beige mice. The animals received 1 3
108 human allogeneic (to the artery) PBMCs per mouse, injected intraperitone-
ally 1 week after transplantation. Animals were euthanized 4 weeks after coro-
nary artery transplantation and transplanted arteries were removed and frozen
in optimal cutting temperature (OCT) compound (Tissue-Tek) for further
analysis.
Femoral Artery Injury Model
This was done as described previously (Acevedo et al., 2004).
Vein Graft Model
Formouse vein to artery graftingmodel, segments of intrathoracic inferior vena
cava from male, 4- to 5-week-old C57BL/6 mice were interposed into the in-
frarenal aortae of male recipient, 10- to 12-week-old Cdh5CreERT2;mT/mG
mice using an end-to-end microsurgical anastomotic technique.hors
Morphometric Analysis
To harvest transplanted grafts, artery, or liver, animals were anesthetized and
tissues were perfused with normal saline and 4%paraformaldehyde (PFA). For
cryosection preparation, grafts were isolated from anesthetized mice, fixed in
4% PFA overnight at 4C, cryoprotected 6 hr in 15% sucrose at 4C, and
embedded in OCT (Tissue-Tek).
Immunofluorescence Staining
Frozen blocks were sectioned at 6 mm intervals. For frozen tissue sections,
slides were fixed in acetone for 10 min at 20C. For paraffin sections, slides
were dewaxed in xylene, and antigen retrieval was performed by boiling
for 20 min in citrate buffer (10 mM [pH 6.0]) and rehydrated. After washing
three times with PBS, tissue sections were incubated with the following
primary antibodies diluted in blocking solution (10% BSA and horse serum
in PBS) overnight at 4C in a humidified chamber: anti-human SM a-actin-
APC (1:10); rabbit anti-Notch3 (1:100); rabbit anti-collagen 1 (1:100); rabbit
anti-SM22a (1:100). Sections were washed three times with TBS, incubated
with appropriate Alexa Fluor 488, 594, or 633 conjugated secondary anti-
bodies diluted 1:1,000 in blocking solution for 2 hr at room temperature,
washed again three times, and mounted on slides with Prolong Gold mounting
reagent with DAPI (Invitrogen). Images were captured using Velocity software
and quantifications performed using ImageJ (NIH).
Computer Assisted Image Analysis (Quantitative IF)
Procollagen and collagen positive area were measured using NIH Image 1.60.
Neointima thickness was measured from 4 regions of a section along a cross,
calculated the average from 5 serial cross-sections, 150 mm apart for each
graft, using computer-assisted image analysis and NIH Image 1.60. For
evaluation of aSMA+/Cdh5-GFP+ or Notch3+/Cdh5-GFP+ cells, at least ten
sections 150 mm apart per graft were analyzed for colocation of endothelial
and smooth muscle markers using immunofluorescent staining imaged under
103 magnification.
Statistical Analysis
Analysis was performed using GraphPad Prism software v.5. All data are pre-
sented asmean ±SD, and two group comparisonswere done with a two-tailed
Student’s t test. A value of p < 0.05 was taken as statistically significant.
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